Skip to content

Effect of Shock Waves Therapy on Chronic Anal Fissure

Effect of Shock Waves Therapy on Anal Fissure

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04793347
Enrollment
20
Registered
2021-03-11
Start date
2021-03-10
Completion date
2021-05-30
Last updated
2021-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Anal Fissure

Brief summary

the study conducted to assess if there is an effect of Extracorporeal Shock Wave Treatment on anal fissure

Detailed description

Design of the study: A prospective, randomized, blind, paired (right/left) comparison. Materials: Measurement tool: * healing of anal fissure, * Wexner Constipation Scoring System * anal pain intensity by means of a 10-point visual analogue scale (VAS) Therapeutic instruments: •. shock waves • topical application of 0.4% glyceryl trinitrate (GTN) ointment Methods: • Testing procedures: The assessment will be performed before commencing treatment, after 4 and 8 weeks of the treatment. • Treatment procedures: Patients will be assigned randomly into two groups equal in number: shock waves Group: twenty patients will receive the shockwaves on perianal area of for 4 weeks (3 sessions /week). control Group: twenty patients will receive the recommended routine medical treatment include topical application of 0.4% glyceryl trinitrate (GTN) ointment only..

Interventions

DEVICEshock master (shock waves device)

device produces shock waves

Sponsors

Cairo University
CollaboratorOTHER
amr bayoumi salama
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* patient with chronic anal fissure * symptomatic for at least 6 months * failed conservative measures

Exclusion criteria

* Pregnant women, * cardiac patients, * patients with a pacemaker, * low molecular heparin or warfarin treatment, * neurological disease,

Design outcomes

Primary

MeasureTime frameDescription
VASup to 3 monthsassessment of pain

Secondary

MeasureTime frameDescription
wexener scaleup to 3 monthsassess the constipation

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026